Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

The US Food and Drug Administration (FDA) has approved the thrombolytic tenecteplase (TNKase, Genentech) for treatment of acute ischemic stroke in adults. The drug is administered as a single, ...

Collecting and documenting disability status at an Enhancing Oncology Model site: Outcomes of an ASCO Quality Training Project. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

The bolus thrombolytic, tenecteplase, was non-inferior to alteplase, which is given by a bolus followed by an infusion, for functional outcomes in acute ischemic stroke patients treated within 4½ ...